Journal
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS
Volume 57, Issue 4, Pages 231-238Publisher
WILEY
DOI: 10.1002/jlcr.3155
Keywords
copper metabolism; radiocopper; tumour imaging; Wilson's disease; Alzheimer's disease
Funding
- EPSRC [EP/I021949/1]
- Engineering and Physical Sciences Research Council [EP/I021949/1] Funding Source: researchfish
- EPSRC [EP/I021949/1] Funding Source: UKRI
Ask authors/readers for more resources
The redox-active transition metal copper is an essential trace element for growth and development and serves as a structural or catalytic cofactor for many enzymes in a range of physiological processes. Mammalian copper homeostasis is tightly regulated, and an imbalance in copper metabolism is implicated in various pathological disorders. Radioactive copper isotopes, in particular Cu-64 (t(1/2)=12.7h) and Cu-67 (t(1/2)=62.01h), have made important contributions to the understanding of copper metabolism in health and disease. This review gives a brief account of how radiolabelled copper(II) salts and bioreductive copper complexes have been used to trace copper uptake, transport and efflux in vitro and in vivo. Recently, positron emission tomography (PET) has emerged as a noninvasive tool to image copper metabolism in living subjects and Cu-64-PET is investigated for the study of copper-related neurological disorders, genetic diseases and cancer. Copyright (c) 2014 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available